Beyond Sinus Rhythm: Rhythm Control and Mechanism-Based Secondary Prevention in Atrial Fibrillation-Related Stroke

Area of Science:

• Cardiology
• Neurology
• Stroke Medicine

Background:

• Atrial fibrillation (AF) is a major cause of ischemic stroke, systemic embolism, heart failure, and mortality.
• Oral anticoagulation, particularly direct oral anticoagulants (DOACs), is crucial for secondary stroke prevention in AF patients.
• Breakthrough ischemic strokes can occur despite anticoagulation, stemming from diverse mechanisms like inadequate drug exposure or atrial cardiomyopathy.

Purpose of the Study:

• To evaluate the efficacy of catheter ablation plus edoxaban versus edoxaban alone for secondary stroke prevention in patients with recent ischemic stroke and AF.
• To assess the role of rhythm control strategies in managing residual stroke risk in atrial fibrillation.

Main Methods:

• The STABLED trial randomized patients with recent ischemic stroke and AF to receive catheter ablation plus edoxaban or edoxaban alone.
• Outcomes assessed included recurrent ischemic stroke, systemic embolism, all-cause mortality, and heart failure hospitalization.

Main Results:

• Catheter ablation added to edoxaban did not significantly reduce the composite endpoint of recurrent ischemic stroke, systemic embolism, all-cause mortality, or heart failure hospitalization compared to edoxaban alone.
• While rhythm control offers benefits for symptom relief and AF burden, it does not appear sufficient as a standalone strategy for secondary stroke prevention.

Conclusions:

• Rhythm control, including catheter ablation, is not superior to anticoagulation alone for preventing recurrent ischemic stroke in AF patients post-stroke.
• Future secondary stroke prevention strategies must integrate optimized anticoagulation, early rhythm control, and a thorough investigation of underlying stroke mechanisms.